Mitochondrial remodeling in heart failure with reduced ejection fraction.
- 1School of Life Science and Technology, Shandong Second Medical University, Weifang, China.
Abstract
Extensive mitochondrial remodeling occurs during heart failure with reduced ejection fraction (HFrEF), yielding either protective adaptations that mitigate dysfunction or detrimental alterations that accelerate disease progression. Central to this remodeling are maladaptive metabolic reprogramming, featured by aberrant fuel preference and electron transport chain deficiency, which underlie the depletion of bioenergetic reserves. Concurrently, alterations in reactive oxygen species (ROS)-producing sites and antioxidant system elevate mitochondrial ROS production while diminishing ROS scavenging capacity, fostering a progressively deteriorating redox environment that perpetuates mitochondrial dysfunction. Additional maladaptive changes, including impaired mitochondrial biogenesis, fission-biased mitochondrial dynamics, mitophagy dysregulation, increased mitochondrial membrane permeability, and activation of pro-inflammatory responses, further disrupt mitochondrial homeostasis and exacerbate cardiac injury. Conversely, remodeling of the mitochondrial Ca²⁺ transport system provides adaptive restriction of mitochondrial Ca²⁺, conferring protection against apoptosis. In this review, I will summarize recent evidence demonstrating the molecular and pathophysiological mechanisms related to mitochondrial remodeling in HFrEF. I will delineate the signaling axes and factors that mediate distinct mitochondrial functions and specify how they are remodeled during the progression of heart failure. Different HFrEF etiologies are associated with distinct mitochondrial pathologies, and these will be comprehensively reviewed. I will also discuss the therapeutic potential of mitochondrial targeting in preclinical models and how these insights are translated into novel clinical strategies to improve heart failure management.
Related
- Impaired mitochondrial proteostasis underlies cardiomyocyte bioenergetic dysfunction in a murine 3-hit model of heart failure with preserved ejection fraction
- Mitochondrial heterogeneity across cardiac cell types in heart failure with preserved ejection fraction
- Effectiveness and safety of coenzyme Q10 in people with heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis
- Single-Cell Analysis of Human Heart Failure With Preserved Ejection Fraction
- AL Cardiac Amyloidosis Mimicking Dilated Cardiomyopathy With Reduced Ejection Fraction and Absent Apical Sparing
BibTeX
@article{chen2026mitochondrial,
title = {{Mitochondrial remodeling in heart failure with reduced ejection fraction.}},
author = {Xin Chen},
journal = {Frontiers in physiology},
year = {2026},
month = oct,
doi = {10.3389/fphys.2026.1958014},
url = {https://europepmc.org/article/MED/42909325},
note = {CC BY},
}
RIS
TY - JOUR
TI - Mitochondrial remodeling in heart failure with reduced ejection fraction.
AU - Xin Chen
PY - 2026
DA - 2026/10/07
JO - Frontiers in physiology
DO - 10.3389/fphys.2026.1958014
UR - https://europepmc.org/article/MED/42909325
AB - Extensive mitochondrial remodeling occurs during heart failure with reduced ejection fraction (HFrEF), yielding either protective adaptations that mitigate dysfunction or detrimental alterations that accelerate disease progression. Central to this remodeling are maladaptive metabolic reprogramming, featured by aberrant fuel preference and electron transport chain deficiency, which underlie the depletion of bioenergetic reserves. Concurrently, alterations in reactive oxygen species (ROS)-producing sites and antioxidant system elevate mitochondrial ROS production while diminishing ROS scavenging capacity, fostering a progressively deteriorating redox environment that perpetuates mitochondrial dysfunction. Additional maladaptive changes, including impaired mitochondrial biogenesis, fission-biased mitochondrial dynamics, mitophagy dysregulation, increased mitochondrial membrane permeability, and activation of pro-inflammatory responses, further disrupt mitochondrial homeostasis and exacerbate cardiac injury. Conversely, remodeling of the mitochondrial Ca²⁺ transport system provides adaptive restriction of mitochondrial Ca²⁺, conferring protection against apoptosis. In this review, I will summarize recent evidence demonstrating the molecular and pathophysiological mechanisms related to mitochondrial remodeling in HFrEF. I will delineate the signaling axes and factors that mediate distinct mitochondrial functions and specify how they are remodeled during the progression of heart failure. Different HFrEF etiologies are associated with distinct mitochondrial pathologies, and these will be comprehensively reviewed. I will also discuss the therapeutic potential of mitochondrial targeting in preclinical models and how these insights are translated into novel clinical strategies to improve heart failure management.
SN - 1664-042X
ER -